Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report

被引：3

作者：

Sunagawa, Shawnalyn W. ^{[1
,3
]}

Havens, Joshua P. ^{[1
,2
]}

Podany, Anthony ^{[1
]}

Walker, Bryan ^{[2
]}

Scarsi, Kimberly K. ^{[1
,2
]}

Bares, Sara H. ^{[2
]}

机构：

[1] Univ Nebraska Med Ctr, Coll Pharm, Omaha, NE 68198 USA

[2] Univ Nebraska Med Ctr, Coll Med, Dept Internal Med, Div Infect Dis, Omaha, NE 68198 USA

[3] Univ Nebraska Med Ctr, Dept Pharm Practice & Sci, 986145 Nebraska Med Ctr, Omaha, NE 68198 USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 12期

关键词：

drug-drug interactions; long-acting cabotegravir/rilpivirine; plasma concentrations; rifamycins;

D O I：

10.1093/ofid/ofad604

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug-drug interactions. We present a real-world case of long-acting cabotegravir/rilpivirine co-administered with intravenous rifampin. The combination resulted in both cabotegravir and rilpivirine concentrations falling below 4 times the protein-adjusted IC90.

引用

页数：3